Some compounds discussed are not FDA-approved for weight management
In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
J Clin Oncol Off J Am Soc Clin Oncol 2:98101
Methylcobalamin plays a role in producing and maintaining healthy white blood cells, which are essential for a robust immune response
The antibodies are produced by activated B cells that recognise both pathogen and self-derived peptides
Continued use at this stage means you're administering degraded fragments with minimal to zero tissue repair activity
